Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

5 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
2(40.0%)
Phase 1
2(40.0%)
Phase 3
1(20.0%)
5Total
Phase 2(2)
Phase 1(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT05483868Phase 1Recruiting

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Role: lead

NCT06643884Phase 2Recruiting

Suprachoroidal Administration in Subjects With Metastases to the Choroid

Role: lead

NCT06007690Phase 3Recruiting

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Role: lead

NCT07421739Recruiting

Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

Role: lead

NCT07338968Not Yet Recruiting

A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma

Role: lead

NCT04417530Phase 2Completed

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Role: lead

NCT03052127Phase 1Completed

Study in Subjects With Small Primary Choroidal Melanoma

Role: lead

NCT03941379Recruiting

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Role: lead

NCT05266430Terminated

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

Role: lead

All 9 trials loaded